MRKR
Marker Therapeutics, Inc.
$1.41
-3.42%
$24.3M
No data for this timeframe.
Vol
Market Cap$24.3M
Cap SizeNano Cap
Inst. Holders6 funds
Inst. Value$848.2K
Inst. Activity1 buys / 1 sells
SEC Reports2
Press Releases1
Recent Activity
Mar 20, 2026
SEC
Marker Therapeutics is holding its 2026 annual meeting where shareholders will vote on several proposals, including the
DEFA14A — Impact 4/10
Mar 19, 2026
SEC
Marker Therapeutics reported its 2025 financial results and provided clinical updates, highlighting a 66% objective resp
8-K — Impact 6/10
Inst.
TWO SIGMA INVESTMENTS, LP — DOUBLED
98,141 shares ($146.2K)
Inst.
MORGAN STANLEY — NEAR_EXIT
15 shares ($22.00)
May 13, 2026
earnings_calendar
MRKR Q1 2026 Earnings Scheduled — 2026-05-13
Mar 18, 2026
Press
Marker Therapeutics reported financial results for 2025, highlighting a net loss increase to $12.2 million despite lower
Impact 6/10
Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$7.87 (Dec 2025)
Current $1.41
Low $5.60
Median $8.00
High $10.00
3 analysts
$5.60
$10.00
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Dec 8, 2025 | HC Wainwright & Co. | INITIATE | Buy |
| Apr 1, 2025 | WBB Securities | REITERATE | Strong Buy → Strong Buy |
| Mar 5, 2025 | Canaccord Genuity | INITIATE | Buy |
| Apr 30, 2024 | Ladenburg Thalmann | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.16 ▲ +11.1% | $-0.16 — $-0.16 | 45% YoY | 1 |
| Next Q | $-0.12 ▲ +7.7% | $-0.12 — $-0.12 | 0% YoY | 1 |
| Current FY | $-0.55 ▲ +9.8% | $-0.55 — $-0.55 | 28% YoY | 1 |
| Next FY | $-0.17 ▲ +10.5% | $-0.17 — $-0.17 | 69% YoY | 1 |
Latest Reports
NEUTRAL
DEFA14A
4/10
Marker Therapeutics is holding its 2026 annual meeting where shareholders will vote on several proposals, including the
Mar 20, 2026
MIXED
8-K
6/10
Marker Therapeutics reported its 2025 financial results and provided clinical updates, highlighting a 66% objective resp
Mar 19, 2026
MIXED
Press
6/10
Marker Therapeutics reported financial results for 2025, highlighting a net loss increase to $12.2 million despite lower
Mar 18, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $515.7K | — |
| RENAISSANCE TECHNOLOGIES LLC | $184.2K | ADD |
| TWO SIGMA INVESTMENTS, LP | $146.2K | DOUBLED |
| BANK OF AMERICA CORP | $1.7K | TRIM |
| WELLS FARGO & COMPANY/MN | $361.00 | — |
6 institutional holders with $848.2K total value (569,248 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, TWO.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 346,074 | $515.7K | 60.8% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 123,650 | $184.2K | 21.7% | ADD +53.0% |
| 3 | TWO SIGMA INVESTMENTS, LP | 98,141 | $146.2K | 17.2% | DOUBLED +168.6% |
| 4 | BANK OF AMERICA CORP /DE/ | 1,126 | $1.7K | 0.2% | TRIM -65.5% |
| 5 | WELLS FARGO & COMPANY/MN | 242 | $361.00 | 0.0% | — |
| 6 | MORGAN STANLEY | 15 | $22.00 | 0.0% | NEAR_EXIT -96.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 36,540 | 98,141 | +168.6% | $146.2K | 2025-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 461 | 15 | -96.7% | $22.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 69,442 | 106,250 | +53.0% | $94.8K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 36,540 | — | $32.6K | 2025-Q3 |
| UBS Group AG | DOUBLED | 1,600 | 5,794 | +262.1% | $5.2K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 14,311 | 1,600 | -88.8% | $2.4K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 3,231 | 1,114 | -65.5% | $1.7K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 40,050 | 83,515 | +108.5% | $102.7K | 2025-Q1 |
| UBS Group AG | NEW | — | 14,311 | — | $17.6K | 2025-Q1 |
| FMR LLC | NEAR_EXIT | 12 | 2 | -83.3% | $2.00 | 2025-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 3,408 | 358 | -89.5% | $1.1K | 2024-Q4 |
| CITADEL ADVISORS LLC | EXIT | 13,032 | 0 | -100.0% | $0.00 | 2024-Q4 |
| UBS Group AG | EXIT | 19,104 | 0 | -100.0% | $0.00 | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 1 neutral. Avg impact: 5.0/10.
Historical analyst distribution (last covering-analyst action Dec 2025): 89% buy across 9 analysts — 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$7.87 mean target (Dec 2025)
$5.60 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $1.41 |
| Target Low | $5.60 |
| Target Mean | $7.87 |
| Target Median | $8.00 |
| Target High | $10.00 |
| # Analysts | 3 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.16 | $-0.16 | $-0.16 | 44.8% | +11.1% | 1↑ 0↓ | $0.0B | -20.8% | 1 |
| Next Q 2026-09-30 |
$-0.12 | $-0.12 | $-0.12 | 0.0% | +7.7% | 1↑ 0↓ | $0.0B | -44.7% | 1 |
| Current FY 2026-12-31 |
$-0.55 | $-0.55 | $-0.55 | 28.1% | +9.8% | 1↑ 0↓ | $0.0B | -20.2% | 1 |
| Next FY 2027-12-31 |
$-0.17 | $-0.17 | $-0.17 | 69.1% | +10.5% | 1↑ 0↓ | $0.0B | 609.7% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.160 | |
| 7d ago | $-0.180 | +0.020 |
| 30d ago | $-0.180 | +0.020 |
| 60d ago | $-0.180 | +0.020 |
| 90d ago | $-0.270 | +0.110 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Dec 8, 2025 | HC Wainwright & Co. | INITIATE | — | Buy |
| Apr 1, 2025 | WBB Securities | REITERATE | Strong Buy | Strong Buy |
| Mar 5, 2025 | Canaccord Genuity | INITIATE | — | Buy |
| Apr 30, 2024 | Ladenburg Thalmann | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 13, 2026
earnings_calendar
MRKR Q1 2026 Earnings Scheduled — 2026-05-13
Mar 30, 2026
earnings_calendar
MRKR Q4 2025 Earnings After Market Close — 2026-03-30
Mar 18, 2026
earnings
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
<p align="center"><em>Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin